MDSC checkpoint blockade therapy: a new breakthrough point overcoming immunosuppression in cancer immunotherapy

Despite the success of cancer immunotherapy in treating hematologic malignancies, their efficacy in solid tumors remains limited due to the immunosuppressive tumor microenvironment (TME), which is mainly formed by myeloid-derived suppressor cells (MDSCs). MDSCs not only exert potent immunosuppressive effects that hinder the success of immune checkpoint inhibitors (ICIs) and adaptive cellular therapies, but they also promote tumor advancement through non-immunological pathways, including promoting angiogenesis, driving epithelial-mesenchymal transition (EMT), and contributing to the establishment of pre-metastatic environments. While targeting MDSCs alone or in combination with conventional therapies has shown…

• NN
  National Natural Science Foundation of China

  Awards: 82071772, 2021YFC3300101, 2019YFA0906100, 2022A1515010070
• BA
  Basic and Applied Basic Research Foundation of Guangdong Province

  Awards: 2019YFA0906100, 2022A1515010070, 2021YFC3300101, 82071772